MCID: PHC013
MIFTS: 41

Phaeochromocytoma

Categories: Cancer diseases

Aliases & Classifications for Phaeochromocytoma

MalaCards integrated aliases for Phaeochromocytoma:

Name: Phaeochromocytoma 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0050771

Summaries for Phaeochromocytoma

MalaCards based summary : Phaeochromocytoma is related to multiple endocrine neoplasia iib and protein s deficiency. An important gene associated with Phaeochromocytoma is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Carbon metabolism and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Doxazosin and Phenoxybenzamine have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, thyroid and testes, and related phenotypes are Decreased viability and homeostasis/metabolism

Wikipedia : 72 Pheochromocytoma (PCC) is a neuroendocrine tumor of the medulla of the adrenal glands (originating in... more...

Related Diseases for Phaeochromocytoma

Diseases related to Phaeochromocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 149)
id Related Disease Score Top Affiliating Genes
1 multiple endocrine neoplasia iib 31.4 NF1 RET SDHB SDHD
2 protein s deficiency 29.6 POMC SST
3 paraganglioma 24.3 CHGA NF1 NGF NPY POMC RET
4 multiple endocrine neoplasia iia 10.8
5 diffuse lipomatosis 10.6 CHGA VHL
6 glomangioma 10.6 SDHB SDHD
7 enteric pattern testicular yolk sac tumor 10.5 CHGA NF1
8 primary syphilis 10.5 CHGA SST
9 bone giant cell sarcoma 10.5 CHGA SST
10 glutamate decarboxylase deficiency 10.5 CHGA SST
11 diphtheria 10.5 CHGA NF1
12 spinal muscular atrophy 10.4 CHGA SST
13 gastric gastrinoma 10.4 CHGA SST
14 carcinoid tumors, intestinal 10.4 SDHB SDHC SDHD
15 rete ovarii cystadenofibroma 10.4 CHGA SST
16 paraganglioma and gastric stromal sarcoma 10.4 SDHB SDHC SDHD
17 mercaptolactate-cysteine disulfiduria 10.4 SDHB SDHC SDHD
18 serous surface papilloma 10.4 SDHB SDHC SDHD
19 breast apocrine carcinoma in situ 10.4 NF1 SST
20 pediatric supratentorial ependymoma 10.4 SDHB SDHC SDHD
21 parietal lobe neoplasm 10.4 CHGA POMC
22 cervical keratinizing squamous cell carcinoma 10.4 NF1 SST
23 epidural abscess 10.4 CHGA NF1
24 bladder cancer, childhood 10.4 CHGA SST
25 primary progressive multiple sclerosis 10.4 CHGA SST
26 synovial chondromatosis 10.3 CHGA POMC
27 ovarian carcinosarcoma 10.3 NGF RET
28 functioning pituitary adenoma 10.3 POMC SST
29 prolactin producing pituitary tumor 10.3 POMC SST
30 african histoplasmosis 10.3 POMC SST
31 fallopian tube papillary adenocarcinoma 10.3 CHGA RET
32 internal auditory canal lipoma 10.3 CHGA POMC
33 lung giant cell carcinoma 10.3 CHGA SST
34 lymphoepithelioma-like carcinoma 10.3 POMC SST
35 heart lymphoma 10.3 NGF SST
36 water-clear cell adenoma 10.3 NGF SST
37 volkmann contracture 10.3 CHGA SST
38 medullary thyroid carcinoma, familial 10.3 CHGA RET SST
39 cowden syndrome 3 10.3 CHGA SDHD SST
40 actinobacillosis 10.2 POMC SST
41 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 10.2 CHGA RET SST
42 hiatus hernia 10.2 RET SST
43 endocrine gland cancer 10.2 CHGA SDHD SST
44 strabismus 10.2 POMC SST
45 carcinoma of unknown primary site, childhood 10.2 CHGA NPY SST
46 trabecular follicular adenocarcinoma 10.1 POMC SST
47 early-onset parkinson disease 10.1 POMC RET SST
48 multiple endocrine neoplasia 10.0
49 peritoneal benign neoplasm 10.0 NF1 POMC
50 bronchiectasis 10.0 POMC SST

Graphical network of the top 20 diseases related to Phaeochromocytoma:



Diseases related to Phaeochromocytoma

Symptoms & Phenotypes for Phaeochromocytoma

GenomeRNAi Phenotypes related to Phaeochromocytoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.8 SDHD VHL NF1 RET
2 Decreased viability GR00221-A-2 9.8 RET SDHD VHL NF1
3 Decreased viability GR00221-A-4 9.8 RET SDHD NF1
4 Decreased viability GR00231-A 9.8 RET
5 Decreased viability GR00301-A 9.8 RET VHL
6 Decreased viability GR00381-A-1 9.8 SDHD
7 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 NF1 VHL

MGI Mouse Phenotypes related to Phaeochromocytoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 CHGA NF1 NGF NPY POMC RET
2 cardiovascular system MP:0005385 10.06 RET SDHB SDHD VHL CHGA NF1
3 growth/size/body region MP:0005378 10.06 POMC RET SDHD SST VHL NGF
4 mortality/aging MP:0010768 10.02 CHGA NF1 NGF POMC RET SDHB
5 endocrine/exocrine gland MP:0005379 9.98 CHGA NF1 POMC RET SDHB SDHD
6 neoplasm MP:0002006 9.73 NF1 POMC RET SDHB SDHD VHL
7 no phenotypic analysis MP:0003012 9.63 NGF POMC RET SDHB SST TMEM127
8 normal MP:0002873 9.56 NF1 NGF NPY RET SDHB SDHD
9 renal/urinary system MP:0005367 9.1 CHGA NF1 NPY POMC RET VHL

Drugs & Therapeutics for Phaeochromocytoma

Drugs for Phaeochromocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
2
Phenoxybenzamine Approved Phase 4,Phase 3,Phase 2 59-96-1 4768
3 Adrenergic Agents Phase 4,Phase 3,Phase 2
4 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
5 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3
6 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2
7 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
8 Antihypertensive Agents Phase 4,Phase 3,Phase 2
9 Vasodilator Agents Phase 4,Phase 3,Phase 2
10
Somatostatin Approved Phase 2, Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
11
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
12
Ifosfamide Approved Phase 3 3778-73-2 3690
13
Lenograstim Approved Phase 3 135968-09-1
14
Mechlorethamine Approved Phase 3 51-75-2 4033
15
Doxil Approved June 1999 Phase 3,Phase 2 31703
16 3-Iodobenzylguanidine Phase 3,Phase 2,Phase 1
17 Radiopharmaceuticals Phase 3,Phase 2,Phase 1
18 Hormone Antagonists Phase 2, Phase 3,Phase 1
19 Hormones Phase 2, Phase 3,Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
21 Alkylating Agents Phase 3,Phase 2,Phase 1
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
24 Isophosphamide mustard Phase 3
25 Topoisomerase Inhibitors Phase 3,Phase 2
26
Indinavir Approved Phase 2 150378-17-9 5362440
27
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
28
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
29 Racepinephrine Approved Phase 2
30
Carbidopa Approved Phase 2 28860-95-9 34359 38101
31
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
32
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
33
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
34
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
35
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
36
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
37
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
38
Tamoxifen Approved Phase 2 10540-29-1 2733526
39
Melphalan Approved Phase 2 148-82-3 4053 460612
40
Pancrelipase Approved Phase 2 53608-75-6
41
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
42
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
43
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
44
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
45
Lenvatinib Approved Phase 2 417716-92-8
46
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
47
nivolumab Approved Phase 2 946414-94-4
48
Pembrolizumab Approved Phase 2 1374853-91-4
49
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
50
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538

Interventional clinical trials:

(show top 50) (show all 82)

id Name Status NCT ID Phase Drugs
1 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
2 Phenoxybenzamine Versus Doxazosin in PCC Patients Recruiting NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
3 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
4 Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
8 Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3 Phenoxybenzamine;Doxazosin
9 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
10 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 131MIBG to Treat Malignant Pheochromocytoma Completed NCT00028106 Phase 2 [131]I-MIBG;6-[18F]Fluorodopamine;[123]I-MIBG
12 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Completed NCT00843037 Phase 2 Sunitinib
13 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
14 RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid Completed NCT01152827 Phase 2 RAD001
15 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2 Ultratrace Iobenguane (MIBG) I 131
16 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
17 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
18 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
19 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
20 RAD001 and Erlotinib in Patients With Neuroendocrine Tumors Completed NCT00843531 Phase 2 RAD001;erlotinib
21 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma Recruiting NCT01371201 Phase 2 Sunitinib;Placebo
22 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Recruiting NCT03206060 Phase 2 Lu-177-DOTATATE;Ga-68-DOTATATE;Amino Acid
23 Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Recruiting NCT03008369 Phase 2 Lenvatinib
24 Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2 Cabozantinib
25 Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Recruiting NCT00107289 Phase 2
26 A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer Recruiting NCT03165721 Phase 2 SGI-110 (guadecitabine)
27 Phase 2 Study of ONC201 in Neuroendocrine Tumors Recruiting NCT03034200 Phase 2 ONC201
28 MIBG Therapy for Patients With MIBG Avid Tumors Recruiting NCT02378428 Phase 2 MIBG
29 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Recruiting NCT02936323 Phase 1, Phase 2 PEN-221
30 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
31 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
32 A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
33 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting NCT01967576 Phase 2 Axitinib (AG-013736)
34 Dovitinib in Neuroendocrine Tumors Active, not recruiting NCT01635907 Phase 2 Dovitinib
35 Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Terminated NCT01340794 Phase 2 Pazopanib Hydrochloride
36 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
37 Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery Withdrawn NCT00770705 Phase 2 Phenoxybenzamine
38 ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Completed NCT00339131 Phase 1 Ultratrace iobenguane I 131
39 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
40 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
41 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
42 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1 everolimus;vatalanib
43 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
44 Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Withdrawn NCT01941849 Phase 1 Vandetanib
45 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
46 Evaluation of Plasma Catecholamine Concentration During Surgery Unknown status NCT00948181
47 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335
48 Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma Approved for marketing NCT00730444 Iobenguane I 123 Injection
49 Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma Completed NCT01022515
50 Diagnosis and Treatment of Pheochromocytoma Completed NCT00001229

Search NIH Clinical Center for Phaeochromocytoma

Genetic Tests for Phaeochromocytoma

Anatomical Context for Phaeochromocytoma

MalaCards organs/tissues related to Phaeochromocytoma:

39
Adrenal Gland, Thyroid, Testes, Lung, Liver, Heart, Endothelial

Publications for Phaeochromocytoma

Articles related to Phaeochromocytoma:

(show top 50) (show all 617)
id Title Authors Year
1
Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades. ( 28605116 )
2017
2
Perioperative I+-receptor blockade in phaeochromocytoma surgery: an observational case series. ( 28100521 )
2017
3
Perioperative management of a large, late presenting phaeochromocytoma. ( 28100576 )
2017
4
Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma. ( 27856506 )
2017
5
Hypertensive emergency masquerading as phaeochromocytoma: a report of two cases. ( 28784870 )
2017
6
Veno-arterial extracorporeal membrane oxygenation for severe cardiogenic shock secondary to phaeochromocytoma crisis. ( 28911298 )
2017
7
Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis. ( 28746746 )
2017
8
Phaeochromocytoma and Paraganglioma Excision Involving the Great Vessels. ( 28856331 )
2017
9
Concomitant multiple myeloma and probable phaeochromocytoma in a cat. ( 28839945 )
2017
10
Review of sequencing platforms and their applications in phaeochromocytoma and paragangliomas. ( 28693800 )
2017
11
Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline SDHx Gene Mutation. ( 28179334 )
2017
12
Significant decreases in blood propofol concentrations during adrenalectomy for phaeochromocytoma. ( 28548279 )
2017
13
Is there an optimal preoperative management strategy for phaeochromocytoma/paraganglioma? ( 27696513 )
2017
14
A rare cause of hypertension in pregnancy: Phaeochromocytoma. ( 28680468 )
2017
15
Screening for phaeochromocytoma and paraganglioma: impact of using supine reference intervals for plasma metanephrines with samples collected from fasted/seated patients. ( 27166307 )
2016
16
Disease-modifying polymorphisms and C609Y mutation of RET associated with high penetrance of phaeochromocytoma and low rate of MTC in MEN2A. ( 27994876 )
2016
17
Occurrence of phaeochromocytoma tumours in RET mutation carriers - a single-centre study. ( 26884116 )
2016
18
Inappropriate adrenoreceptor blockade prior to phaeochromocytoma removal is perhaps a 'timely reappraisal'? ( 27332792 )
2016
19
Phaeochromocytoma presenting with labile blood pressures following coronary artery bypass grafting. ( 27699857 )
2016
20
Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. ( 26839173 )
2016
21
Phaeochromocytoma and transient left ventricular apical ballooning syndrome. ( 27505337 )
2016
22
Preoperative alpha-blockade in phaeochromocytoma and paraganglioma: is it always necessary? ( 27864838 )
2016
23
Successful management of phaeochromocytoma in the third trimester of pregnancy with the use of rapid sequential alpha-adrenergic blockage. ( 26792534 )
2016
24
Malignant phaeochromocytoma with cavoatrial extension imaged with (123)I-MIBG. ( 26932713 )
2016
25
Phaeochromocytoma and Paraganglioma. ( 27888488 )
2016
26
Bowel perforation complicating an ACTH-secreting phaeochromocytoma. ( 28203371 )
2016
27
Cardiogenic shock induced by a voluminous phaeochromocytoma rescued by concomitant extracorporeal life support and open left adrenalectomy. ( 27068551 )
2016
28
Diagnosis and Management of Hereditary Phaeochromocytoma and Paraganglioma. ( 27075351 )
2016
29
Doxazosin treatment of phaeochromocytoma during pregnancy: placental transfer and disposition in breast milk. ( 27194370 )
2016
30
Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. ( 26998836 )
2016
31
Invasive phaeochromocytoma presenting as a right atrial mass. ( 26632094 )
2016
32
Phaeochromocytoma presenting as an acute coronary syndrome. ( 27797837 )
2016
33
Primary hypercortisolism and phaeochromocytoma next to, but not related to, each other. ( 27073149 )
2016
34
Endoprosthetic reconstruction for metastatic phaeochromocytoma in the distal femur: A case report. ( 28018063 )
2016
35
European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. ( 27048283 )
2016
36
Rapid-sequence MRI for long-term surveillance for paraganglioma and phaeochromocytoma in patients with succinate dehydrogenase (SDHx) mutations. ( 27634942 )
2016
37
Recurrence of phaeochromocytoma in pregnancy in a patient with multiple endocrine neoplasia 2A: a case report and review of literature. ( 27808580 )
2016
38
ANNALS EXPRESS: Single-centre study of the diagnostic performance of plasma metanephrines with seated sampling for the diagnosis of phaeochromocytoma/paraganglioma. ( 27170024 )
2016
39
Unusual presentation of phaeochromocytoma. ( 27166010 )
2016
40
Phaeochromocytoma presenting with ST segment elevation myocardial infarction. ( 26857585 )
2016
41
Recurrent phaeochromocytoma along the laparoscopic portal sites. ( 25735583 )
2015
42
Perioperative anaesthetic management of phaeochromocytoma associated with uncorrected tetralogy of Fallot. ( 26903678 )
2015
43
Cushing's disease and co-existing phaeochromocytoma. ( 26184502 )
2015
44
Neurofibromatosis-related phaeochromocytoma: two cases with large tumours and elevated plasma methoxytyramine. ( 26273474 )
2015
45
Laparoscopic adrenalectomy for phaeochromocytoma: a case series. ( 26645753 )
2015
46
Laparoscopic adrenalectomy for phaeochromocytoma: a case series. ( 26922446 )
2015
47
Diagnosing phaeochromocytoma/paraganglioma in a patient presenting with critical illness: biochemistry versus imaging. ( 25683095 )
2015
48
Phaeochromocytoma with hypercortisolism and hypercalcaemia. ( 26446319 )
2015
49
Adrenaline rush: an unusual presentation of phaeochromocytoma. ( 26323979 )
2015
50
Recurrence of Phaeochromocytoma and Abdominal Paraganglioma After Initial Surgical Intervention. ( 26170485 )
2015

Variations for Phaeochromocytoma

Expression for Phaeochromocytoma

Search GEO for disease gene expression data for Phaeochromocytoma.

Pathways for Phaeochromocytoma

GO Terms for Phaeochromocytoma

Cellular components related to Phaeochromocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 respiratory chain complex II GO:0045273 8.96 SDHB SDHC
2 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.8 SDHB SDHC SDHD

Biological processes related to Phaeochromocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.67 NF1 SST TMEM127 VHL
2 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.43 NF1 NGF
3 aerobic respiration GO:0009060 9.4 SDHB SDHC
4 regulation of blood pressure GO:0008217 9.33 CHGA NPY POMC
5 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 9.32 NF1 RET
6 regulation of appetite GO:0032098 9.26 NPY POMC
7 mitochondrial electron transport, succinate to ubiquinone GO:0006121 8.96 SDHAF2 SDHD
8 tricarboxylic acid cycle GO:0006099 8.92 SDHAF2 SDHB SDHC SDHD

Molecular functions related to Phaeochromocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.5 NPY POMC SST
2 electron carrier activity GO:0009055 9.43 SDHB SDHC SDHD
3 ubiquinone binding GO:0048039 9.16 SDHB SDHD
4 neuropeptide hormone activity GO:0005184 9.07 NPY
5 succinate dehydrogenase (ubiquinone) activity GO:0008177 8.96 SDHB SDHD
6 succinate dehydrogenase activity GO:0000104 8.62 SDHC SDHD

Sources for Phaeochromocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....